Trial · NCT03275350
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed | Extended-release Naltrexone (XR-NTX) | 12 Weeks | 23 | Participants | |
| Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed | Treatment as Usual (TAU) | 12 Weeks | 21 | Participants | |
| Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed | Extended-release Naltrexone (XR-NTX) | 24 Weeks | 29 | Participants | |
| Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed | Treatment as Usual (TAU) | 24 Weeks | 29 | Participants | |
| Number of Participants With HIV Viral Suppression, Complete Case | Extended-release Naltrexone (XR-NTX) | 12 Weeks | 23 | Participants | |
| Number of Participants With HIV Viral Suppression, Complete Case | Treatment as Usual (TAU) | 12 Weeks | 19 | Participants | |
| Number of Participants With HIV Viral Suppression, Complete Case | Extended-release Naltrexone (XR-NTX) | 24 Weeks | 26 | Participants | |
| Number of Participants With HIV Viral Suppression, Complete Case | Treatment as Usual (TAU) | 24 Weeks | 26 | Participants | |
| Number of Participants With HIV Viral Suppression, Per-protocol | Extended-release Naltrexone (XR-NTX) | 12 weeks | 11 | Participants | |
| Number of Participants With HIV Viral Suppression, Per-protocol | Treatment as Usual (TAU) | 12 weeks | 16 | Participants | |
| Number of Participants With HIV Viral Suppression, Per-protocol | Extended-release Naltrexone (XR-NTX) | 24 weeks | 15 | Participants | |
| Number of Participants With HIV Viral Suppression, Per-protocol | Treatment as Usual (TAU) | 24 weeks | 23 | Participants | |
| Veterans Aging Cohort Study (VACS) Index | Extended-release Naltrexone (XR-NTX) | Baseline | 65.1 | Standard Deviation 18.1 | score on a scale |
| Veterans Aging Cohort Study (VACS) Index | Treatment as Usual (TAU) | Baseline | 68.4 | Standard Deviation 24.7 | score on a scale |
| Veterans Aging Cohort Study (VACS) Index | Extended-release Naltrexone (XR-NTX) | 24 Weeks | 54.4 | Standard Deviation 20.7 | score on a scale |
| Veterans Aging Cohort Study (VACS) Index | Treatment as Usual (TAU) | 24 Weeks | 63.5 | Standard Deviation 25.4 | score on a scale |
| CD4 Count | Extended-release Naltrexone (XR-NTX) | Baseline | 380.7 | Standard Deviation 248.2 | cells/mm3 |
| CD4 Count | Treatment as Usual (TAU) | Baseline | 439.8 | Standard Deviation 336.6 | cells/mm3 |
| CD4 Count | Extended-release Naltrexone (XR-NTX) | 24 Weeks | 459.1 | Standard Deviation 249.1 | cells/mm3 |
| CD4 Count | Treatment as Usual (TAU) | 24 Weeks | 505.1 | Standard Deviation 349.1 | cells/mm3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03275350/results